Nuheara Limited (NUH.AX)
| Previous close | 0.0180 |
| Open | 0.0190 |
| Bid | 0.0170 x 197574900 |
| Ask | 0.0180 x 26031200 |
| Day's range | 0.0170 - 0.0190 |
| 52-week range | 0.0140 - 0.0600 |
| Volume | |
| Avg. volume | 5,053,759 |
| Market cap | 31.404M |
| Beta (5Y monthly) | 1.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0050 |
| Earnings date | 21 Feb 2022 - 25 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Nuheara Welcomes Landmark FDA Proposed Rules for Over-the-Counter Hearing Aids
Nuheara is already undertaking clinical trials of a self-fit hearing aid and plans to file a 510(k) to launch one of the first products availableSAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nuheara (ASX: NUH), the developer of smart and affordable hearing solutions that transform the way people hear, welcomes the U.S. Food and Drug Administration (FDA) issuing its landmark proposal intended to improve access to and reduce the cost of hearing aid technology for millions of Americans[1]. The U
- Simply Wall St.
Here's Why We're Not Too Worried About Nuheara's (ASX:NUH) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
As Hearables Sector Matures, Nuheara Deepens Audiology, Hearing Health and Product Development Credentials
Augmented hearables pioneer readies to drive further disruption in the hearing health sectorSAN FRANCISCO, June 21, 2021 (GLOBE NEWSWIRE) -- With mild-to-moderate hearing loss on the rise, and the Over-the-Counter (OTC) Hearing Aid Act soon to be implemented, Nuheara (ASX:NUH) today announced a string of senior hearing-health sector appointments to strengthen its market position. The augmented hearables pioneer is at the forefront of bringing affordable and accessible hearing solutions to the ma
